D-dimer test characteristics in cancer and non-cancer patients
| Reference . | D-dimer assay . | Patient type . | Sample size . | VTE prevalence (%) . | Sensitivity (%) (95% CI) . | Specificity (%) (95% CI) . | NPV (%) (95% CI) . | Negative test, No. (%) . |
|---|---|---|---|---|---|---|---|---|
| Diagnosis of DVT | ||||||||
| Lee et al21 | SimpliRED | No cancer | 947 | 14.6 | 82.6 (12.4-17.0) | 82.2 (79.4-84.8) | 96.5 (94.9-97.8) | NR |
| Cancer | 121 | 48.8 | 86.4 (75.0- 94.0) | 48.4 (35.5-61.4) | 78.9 (62.7-90.4) | NR | ||
| ten Wolde et al28 | SimpliRED | No cancer | 1522 | 22.0 | 93.0 (90.0-96.0) | 64.0 (62.0-67.0) | 97.0 (96.0-98.0) | 782 (51.4) |
| Cancer | 217 | 40.0 | 98.0 (92.0-100.0) | 48.0 (39.0-59.0) | 97.0 (89.0-100) | 64 (29.5) | ||
| Di Nisio et al16 * | SimpliRED | No cancer | 1822 | 22.0 | 90.0 (85.0-93.0) | 64.0 (61.0-66.0) | 97.0 (96.0-98.0) | 913 (50.1) |
| Cancer | 244 | 41.0 | 94.0 (80.0-90.0) | 51.0 (42.0-60.0) | 97.0 (88.0-99.0) | 73 (29.9) | ||
| Schutgens et al26 | Minutex | No cancer | 508 | 35.0 | 99.0 (NR) | 30.0 (NR) | 98.0 (NR) | 100 (19.6) |
| Cancer | 47 | 62.0 | 100.0 (NR) | 22.0 (NR) | 100.0 (NR) | 4 (8.5) | ||
| Shitrit et al27 | Miniquant | All patients | 126 | 27.8 | 94.0 (NR) | 57.0 (NR) | 54.0 (NR) | NR |
| Cancer | 21 | 61.9 | 91.0 (NR) | 0.0 (NR) | 38.0 (NR) | NR | ||
| Bates et al22 † | MDA | All patients | 595 | 19.0 | 96.0 (90.0-99.0) | 45.0 (40.0-49.0) | 98.0 (95.0-99.0) | 220 (37) |
| Cancer | 66 | 43.9 | 97.0 (82.0-100) | 46.0 (30.0-63.0) | 94.0 (73.0-100.0) | 18 (27.3) | ||
| Bates et al23 | MDA | All patients | 556 | 10.1 | 98.2 (90.4-100) | 60.4 (56.1-64.7) | 99.7 (98.2-100) | 303 (62.5) |
| Cancer | 50 | 34.0 | 100 (80.5-100) | 45.5 (28.1-63.7) | 100 (78.2-100) | 15 (30) | ||
| Diagnosis of PE | ||||||||
| Di Nisio et al24 | Tinaquant | No cancer | 447 | 19.0 | 93.0 (87.0-98.0) | 53.0 (48.0-58.0) | 97.0 (95.0-99.0) | 199 (44.5) |
| Cancer | 72 | 26.0 | 100 (82.0-100) | 21.0 (10.0-32.0) | 100 (72.0-100) | 11 (15.3) | ||
| Righini et al25 | VIDAS | No cancer | 1554 | 23.0 | 100 (99.0-100) | 41.0 (39.0-44.0) | 100 (99.0-100) | 494 (32) |
| Cancer | 164 | 33.0 | 100 (93.0-100) | 16.0 (11.0-24.0) | 100 (82.0-100) | 18 (11) |
| Reference . | D-dimer assay . | Patient type . | Sample size . | VTE prevalence (%) . | Sensitivity (%) (95% CI) . | Specificity (%) (95% CI) . | NPV (%) (95% CI) . | Negative test, No. (%) . |
|---|---|---|---|---|---|---|---|---|
| Diagnosis of DVT | ||||||||
| Lee et al21 | SimpliRED | No cancer | 947 | 14.6 | 82.6 (12.4-17.0) | 82.2 (79.4-84.8) | 96.5 (94.9-97.8) | NR |
| Cancer | 121 | 48.8 | 86.4 (75.0- 94.0) | 48.4 (35.5-61.4) | 78.9 (62.7-90.4) | NR | ||
| ten Wolde et al28 | SimpliRED | No cancer | 1522 | 22.0 | 93.0 (90.0-96.0) | 64.0 (62.0-67.0) | 97.0 (96.0-98.0) | 782 (51.4) |
| Cancer | 217 | 40.0 | 98.0 (92.0-100.0) | 48.0 (39.0-59.0) | 97.0 (89.0-100) | 64 (29.5) | ||
| Di Nisio et al16 * | SimpliRED | No cancer | 1822 | 22.0 | 90.0 (85.0-93.0) | 64.0 (61.0-66.0) | 97.0 (96.0-98.0) | 913 (50.1) |
| Cancer | 244 | 41.0 | 94.0 (80.0-90.0) | 51.0 (42.0-60.0) | 97.0 (88.0-99.0) | 73 (29.9) | ||
| Schutgens et al26 | Minutex | No cancer | 508 | 35.0 | 99.0 (NR) | 30.0 (NR) | 98.0 (NR) | 100 (19.6) |
| Cancer | 47 | 62.0 | 100.0 (NR) | 22.0 (NR) | 100.0 (NR) | 4 (8.5) | ||
| Shitrit et al27 | Miniquant | All patients | 126 | 27.8 | 94.0 (NR) | 57.0 (NR) | 54.0 (NR) | NR |
| Cancer | 21 | 61.9 | 91.0 (NR) | 0.0 (NR) | 38.0 (NR) | NR | ||
| Bates et al22 † | MDA | All patients | 595 | 19.0 | 96.0 (90.0-99.0) | 45.0 (40.0-49.0) | 98.0 (95.0-99.0) | 220 (37) |
| Cancer | 66 | 43.9 | 97.0 (82.0-100) | 46.0 (30.0-63.0) | 94.0 (73.0-100.0) | 18 (27.3) | ||
| Bates et al23 | MDA | All patients | 556 | 10.1 | 98.2 (90.4-100) | 60.4 (56.1-64.7) | 99.7 (98.2-100) | 303 (62.5) |
| Cancer | 50 | 34.0 | 100 (80.5-100) | 45.5 (28.1-63.7) | 100 (78.2-100) | 15 (30) | ||
| Diagnosis of PE | ||||||||
| Di Nisio et al24 | Tinaquant | No cancer | 447 | 19.0 | 93.0 (87.0-98.0) | 53.0 (48.0-58.0) | 97.0 (95.0-99.0) | 199 (44.5) |
| Cancer | 72 | 26.0 | 100 (82.0-100) | 21.0 (10.0-32.0) | 100 (72.0-100) | 11 (15.3) | ||
| Righini et al25 | VIDAS | No cancer | 1554 | 23.0 | 100 (99.0-100) | 41.0 (39.0-44.0) | 100 (99.0-100) | 494 (32) |
| Cancer | 164 | 33.0 | 100 (93.0-100) | 16.0 (11.0-24.0) | 100 (82.0-100) | 18 (11) |